What the FDA Relabeling of Abacavir Means for You and Your Patient

Highly Active Antiretroviral Therapy

November 2008

Highly Active Anti Therapy has been available for the last 15 years, and there are three groups of drugs that are effective against HIV virus. The earliest group of drugs that became commercially available are the nucleoside reverse transcriptase inhibitors. There are six of them listed here.

Then, there are the nonnucleoside reverse transcriptase inhibitors, and three of these are commercially available and FDA-approved in the United States.

Finally, the protease inhibitors, as illustrated here.

There are two other groups of retroviral therapy that have been available commercially in the last two years. The integrase inhibitors as well as the HIV entry co-receptor antagonists, but those have not made it into the mainstream of combination therapy until recently.

The definition of HAART is defined by a combination of at least two of these drug combinations and the nonnucleoside can be combined with one protease or one nucleoside reverse transcriptase inhibitor or combined with two protease inhibitors.

< Previous Slide

Highly Active Antiretroviral Therapy

Next Slide >

 

Jump to section:

• Introduction
• Highly Active Antiretroviral Therapy
• Abacavir
• FDA Caution and Relabeling
• Abacavir Hypersensitivity
• Abacavir HSR and HLA Gene
• HLA-B Antigens and Alleles
• Naming Conventions - HLA-B*5701
• Chromosome 6
• Detecting HLA Alleles
• HLA-B*5701 Correlations
• HLA-B*5701 Correlations
• Clinical Utility³
• Problems
• If HSR Symptoms are Present⁴
• If HSR Symptoms are Present⁴
• Recommendations for Physicians⁵
• Recommendations for Physicians⁵
• Information for Patients⁵
• Information for Patients⁵
• HLA-B*5701 Genotyping
• References
• Questions?